

# Trial platform: preventing depression relapse in the National Health Service practice using Mindfulness-Based Cognitive Therapy

<b>Submission date</b> 27/06/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 31/08/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 31/07/2012	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Willem Kuyken

### Contact details

University of Exeter  
Mood Disorders Centre  
School of Psychology  
Perry Road  
Exeter  
United Kingdom  
EX4 4QG  
w.kuyken@exeter.ac.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

## Scientific Title

## Acronym

MBCT

## Study objectives

### Aims:

1. To carry out preparatory work necessary to design and conduct an adequately powered, well-controlled, multi-centre randomised controlled effectiveness study of the generalisability of MBCT to real-world National Health Service (NHS) practice settings comparing it to the current treatment of choice (anti-depressant medication)
2. To examine key mechanisms that enhance recovery and prevent relapse via a pilot process-outcome study.

### Objectives:

1. To integrate MBCT into selected primary care service contexts
2. To fully cost MBCT
3. To establish patient throughput numbers
4. To develop training and supervision packages for MBCT therapists
5. To pilot measures of mechanisms of change, health status and cost-effectiveness
6. To estimate MBCT effect sizes in real-world conditions
7. To resolve methodology/design issues for the phase IV study, including necessary sample size (based on points one, two & five above), feasibility/method of randomising patients with remitted depression to pharmacological and MBCT treatment arms and optimal follow-up periods

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

North and East Devon research ethics committee project (reference number: 05/Q2102/77) approval given 8th August 2005.

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

**Study type(s)**

Prevention

**Participant information sheet****Health condition(s) or problem(s) studied**

Depression

**Interventions**

Continuation anti-depressants or Mindfulness-based Cognitive Therapy.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome measure**

In line with previous MBCT randomised controlled trials (RCTs), the primary outcome measure will be a recurrence of depression meeting DSM-IV criteria.

**Secondary outcome measures**

Secondary outcome measures will be residual depressive symptoms (measured by the interviewer-rated Hamilton Depression Scale and self-report Beck Depression Inventory). In line with effectiveness trials examining an interventions generalisability, a novel feature of this study will be extending outcome assessment to health status (using the Medical Outcomes Study [MOS SF-12] instrument), quality of life (using the World Health Organisation Quality of Life [WHOQOL-BREF] instrument), and health costs (using Client Service Receipt Inventory adapted for depression relapse studies).

**Overall study start date**

01/09/2005

**Completion date**

30/09/2007

**Eligibility****Key inclusion criteria**

1. Three or more previous episodes of depression meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria (including the current episode)
2. Aged 18 or older
3. Currently in either partial or full remission from last episode of depression

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

40 in MBCT and 40 in continuation anti-depressants

**Key exclusion criteria**

Co-morbid psychiatric diagnoses that would:

1. Interfere with engaging with MBCT (current substance dependence)
2. Be exacerbated by MBCT (psychosis, very disabling obsessive compulsive disorder) and formal concurrent psychotherapy

**Date of first enrolment**

01/09/2005

**Date of final enrolment**

30/09/2007

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**University of Exeter**

Exeter

United Kingdom

EX4 4QG

**Sponsor information****Organisation**

University of Exeter (UK)

**Sponsor details**

School of Psychology

Perry Road

Exeter

England

United Kingdom

EX4 4QG  
w.kuyken@exeter.ac.uk

**Sponsor type**  
University/education

**Website**  
<http://www.exeter.ac.uk/>

**ROR**  
<https://ror.org/03yghzc09>

## **Funder(s)**

**Funder type**  
Research council

**Funder Name**  
Medical Research Council (MRC) (UK) (ref: G0401161)

**Alternative Name(s)**  
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
United Kingdom

## **Results and Publications**

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/12/2008		Yes	No
<a href="#">Results article</a>	results	01/07/2009		Yes	No
<a href="#">Results article</a>	results	01/06/2010		Yes	No
<a href="#">Results article</a>	results of sub-study on effect on parenting	01/01/2012		Yes	No